These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516 [No Abstract] [Full Text] [Related]
9. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R Ann Intern Med; 2021 May; 174(5):673-679. PubMed ID: 33560862 [TBL] [Abstract][Full Text] [Related]
10. Remdesivir as a broad-spectrum antiviral drug against COVID-19. Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946 [TBL] [Abstract][Full Text] [Related]
11. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Miller MC; Forciea MA; Humphrey LL; Ann Intern Med; 2021 Dec; 174(12):W116-W117. PubMed ID: 34606308 [No Abstract] [Full Text] [Related]
12. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175 [TBL] [Abstract][Full Text] [Related]
13. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug? Thalha AMM; Lee YY; Besari A; Omar SFS J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289 [No Abstract] [Full Text] [Related]
14. Remdesivir (Veklury) for COVID-19. Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491 [No Abstract] [Full Text] [Related]
15. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients. Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154 [No Abstract] [Full Text] [Related]
17. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19. Chua KP; Conti RM JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187 [No Abstract] [Full Text] [Related]
18. USA stockpiling of remdesivir: How should the world respond? Dawoud D; Chalkidou K; Sullivan R; Ruiz FJ; Adler A J Comp Eff Res; 2020 Dec; 9(18):1243-1246. PubMed ID: 33274643 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacodynamics of obeldesivir versus remdesivir. Faghihi I; Yan VC Antimicrob Agents Chemother; 2024 Sep; 68(9):e0096924. PubMed ID: 39133123 [No Abstract] [Full Text] [Related]
20. FDA Approval of Remdesivir - A Step in the Right Direction. Rubin D; Chan-Tack K; Farley J; Sherwat A N Engl J Med; 2020 Dec; 383(27):2598-2600. PubMed ID: 33264539 [No Abstract] [Full Text] [Related] [Next] [New Search]